臨床試驗

Phase 1/2a Study of ANPD001 in Parkinson Disease

NCT：NCT06344026 · ENROLLING_BY_INVITATION

NCT IDNCT06344026

狀態ENROLLING_BY_INVITATION

開始日期2024-01-23

完成時間2030-04-30

SponsorAspen Neuroscience (INDUSTRY)

First posted2024-04-03

Last updated2026-05-14

簡要摘要

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。